CHI's 3rd Annual Early Cancer Surveillance

Only five types of cancer, representing a minority of cancer cases, have individual screening tests recommended for periodic population screening, with moderate to poor compliance and detection results. Developing single cancer screening tests for other types of cancer is impractical, whereas liquid biopsies that can detect signals for many different types of cancer in a single assay offer the potential for breakthrough changes in cancer detection. Many questions need to be addressed for commercialization and widespread adoption of multi-cancer early detection (MCED) tests, with a variety of different classes of biomarkers being developed and evaluated. Progress with different assays and what will be required for clinical validation, regulatory and reimbursement approval, accessibility, and cost-effectiveness of such tests still need to be answered. Get the latest updates from key competitors by attending CHI's 3rd Annual Early Cancer Surveillance conference - part of the Next Generation Dx Summit.